- Home
- FENC vs SLP Comparison
FENC vs SLP Comparison
Compare FENC & SLP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FENC | SLP |
|---|---|---|
| Founded | 1996 | 1996 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | EDP Services |
| Sector | Health Care | Technology |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 384.3M | 371.9M |
| IPO Year | 2010 | 1996 |
Fundamental Metrics
Financial Performance| Metric | FENC | SLP |
|---|---|---|
| Price | $10.76 | $18.43 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | $14.50 | ★ $24.00 |
| AVG Volume (30 Days) | ★ 243.7K | 143.1K |
| Earning Date | 05-12-2026 | 04-09-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | 0.06 | ★ 0.43 |
| Revenue | $44,642,000.00 | ★ $59,577,000.00 |
| Revenue This Year | $65.12 | $3.80 |
| Revenue Next Year | $41.08 | $5.90 |
| P/E Ratio | $179.67 | ★ $42.88 |
| Revenue Growth | N/A | ★ 10.52 |
| 52 Week Low | $5.65 | $11.09 |
| 52 Week High | $13.25 | $21.01 |
Technical Indicators
Market Signals| Indicator | FENC | SLP |
|---|---|---|
| Relative Strength Index (RSI) | 40.04 | 59.43 |
| Support Level | $9.74 | $18.22 |
| Resistance Level | $11.28 | $18.46 |
| Average True Range (ATR) | 0.58 | 0.02 |
| MACD | -0.24 | -0.01 |
| Stochastic Oscillator | 19.77 | 43.75 |
Price Performance
Historical ComparisonAbout FENC Fennec Pharmaceuticals Inc.
Fennec Pharmaceuticals Inc is a commercial-stage biopharmaceutical company. Its product candidate is PEDMARK which is sodium thiosulfate in a novel formulation for the prevention of cisplatin-induced hearing loss, or ototoxicity in children. The company principally operates in the United States.
About SLP Simulations Plus Inc.
Simulations Plus Inc is engaged in the software industry. It develops and produces software for use in pharmaceutical research and education, and provides consulting and contract research services to the pharmaceutical industry. The company's operating segments include Software and services. The company offers software products for pharmaceutical research such as ADMET (Absorption, Distribution, Metabolism, Excretion, and Toxicity). It generates maximum revenue from the software segment. Maximum revenue is earned from USA following EMEA and Asia Pacific.